Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
KKR & Co. Inc., also known as Kohlberg Kravis Roberts & Co., agreed to buy a stake in Cotiviti to accelerate innovation and growth. The American investment firm is acquiring the asset from Veritas Capital Fund Management, L.L.C., a private equity company based in New York City.
KKR & Co. is set to invest $11 billion to acquire a stake in Cotiviti. This amount would be one of the most significant new PEF transactions. On Wednesday, Feb. 14, the company said that KKR and Veritas Capital will have equal shares in the health tech firm once the deal is completed.
Financing for the Deal
The acquisition will boost KKR's portfolio of healthcare analytics investments. According to Axios, the agreement will include $5 billion worth of loans that JPMorgan would manage.
This arrangement with a leading investment company is said to be a major win for the traditional banking sector, which has mostly been yielding buyout financing to private credit companies.
JPMorgan will help KKR with financing its Cotiviti acquisition through loans. In any case, the deal is expected to be completed within the second quarter of this year.
KKR and Veritas Capital's Plans
The Wall Street Journal reported that KKR and Veritas Capital's deal now ranks among the most extensive negotiations in recent times. This is because buyout firms have decelerated dealmaking after the Federal Reserve started marking up interest rates in 2022, making debt to fund acquisitions more expensive and challenging to secure.
Meanwhile, under the agreement, KKR and Veritas will also hand out considerable capital to help accelerate innovation while funding investments for growth. They may expand their business, introduce new product development, and work together on some tech-related opportunities.
"I am excited to continue our partnership with Veritas and welcome KKR as a new partner. Since initially partnering with Veritas in 2016, we have dramatically expanded our scale and enhanced our value proposition to our customers," Cotiviti's chairman, president, and chief executive officer, Emad Rizk, M.D., said in a press release. "I look forward to collaborating with both KKR and Veritas to leverage our highly differentiated solutions to improve the cost and quality within the healthcare system."
Photo by: Cotiviti Press Room
